Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VDPHL01 QD
VDPHL01 · 4 trials · 6 indications
Changes from baseline in non-vellus TAHC using digital image analysis at Month 6.
Subjects will rate their treatment benefit by responding to a hair assessment scale. The proportion of subjects by each response category will be reported at Month 6.
Change from baseline in non-vellus TAHC using digital image analysis at Month 12.
| Arm | Type | Description |
|---|---|---|
| VDPHL01 BID | EXPERIMENTAL | VDPHL01 will be taken orally twice a day (BID), once in the AM and once in the PM for the first 6 months of the study. After month 6, subject will continue VDPHL01 BID for an additional 6 months. |
| VDPHL01 QD and Placebo QD | EXPERIMENTAL | Placebo will be taken orally once a day (QD) in the AM or PM. VDPHL01 will be taken orally once a day (QD) in the AM or PM for the first 6 months of the study. After month 6, subject will continue this same dose regimen for an additional 6 months. |
| Placebo BID with treatment extension to VDPHL01 BID | PLACEBO_COMPARATOR | Placebo will be taken orally twice a day (BID), once in the AM and once in the PM for the first 6 months of the study. After month 6, subject will switch to VDPHL01 BID group, and take VDPHL01 orally twice a day (BID), once in the AM and once in the PM for an additional 6 months. |
| Placebo BID with treatment extension to VDPHL01 QD and Placebo QD | PLACEBO_COMPARATOR | Placebo will be taken orally twice a day (BID), once in the AM and once in the PM for the first 6 months of the study. After month 6, subject will switch to VDPHL01 QD and Placebo QD group, and take placebo orally once a day in the AM or PM; VDPHL01 will be taken orally once a day in the AM or PM for an additional 6 months. |
| VDHPL01 BID | EXPERIMENTAL | VDPHL01 will be taken orally twice a day, once in the AM and once in the PM. |
| VDPHL01 Tablet | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VDPHL01 QD | DRUG | VDPHL01 Extended Release (ER) Tablet |
| Placebo | DRUG | Placebo tablet |
| VDPHL01 BID | DRUG | VDPHL01 Extended Release (ER) Tablet |
| VDPHL01 | DRUG | VDPHL01 Extended Release (ER) Tablet |
Inclusion Criteria: * Subject is a female aged 18-65 years old; * Subject has a clinical diagnosis of mild to moderate AGA; * Subject is in good general health and has adequate renal and hepatic function; * Subject is willing to maintain at least 1/4 inch length hair during the study with the same ...
VDPHL01 is an investigational small molecule being developed for androgenetic alopecia (AGA), also known as male or female pattern baldness. It is a hair growth agent that targets minoxidil. The drug is currently in Phase 3 clinical development and has not been approved by the FDA.
VDPHL01 targets minoxidil, a well-known hair growth agent. It is being studied as a treatment for androgenetic alopecia, which causes hair loss in both men and women. The drug is designed to address the underlying mechanisms of pattern baldness.
VDPHL01 is being developed by Veradermics, Incorporated, a biopharmaceutical company. The company is conducting clinical trials to evaluate the safety and efficacy of VDPHL01 for the treatment of androgenetic alopecia in both male and female patients.
VDPHL01 is currently in Phase 3 clinical development. The company has completed Phase 2 trials and is now conducting Phase 3 studies to further evaluate the drug's safety and efficacy in treating androgenetic alopecia. The drug is investigational and not yet FDA approved.
VDPHL01 is being studied in several clinical trials, including NCT06527365, NCT06724614, NCT06972264, and NCT07146022. These trials are evaluating the drug in males and females with androgenetic alopecia, with some studies specifically focused on male or female patients. All trials are active but not recruiting.
Yes, VDPHL01 is also known as VDPHL01 QD. The 'QD' designation likely refers to a once-daily dosing regimen. Both names refer to the same investigational drug being developed by Veradermics for the treatment of androgenetic alopecia.